Close

Form 6-K Acasti Pharma Inc. For: Jan 02

January 2, 2018 8:21 AM EST

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of: January 2018   Commission File Number: 001-35776

 

 

 

ACASTI PHARMA INC.

(Name of Registrant)

 

 

 

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x            Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨             No  x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

 

 

 

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ACASTI PHARMA INC.
     
     
Date: January 2, 2018 By:  a/s/ Jan D’Alvise
   

Name: Jan D’Alvise

Title: Chief Executive Officer

 

 

 

 

 

 

 

 

EXHIBIT INDEX

 

 

   
Exhibit Description of Exhibit
99.1 Press release dated Janury 2, 2018

 

 

 

 

Exhibit 99.1

 

 

Acasti Pharma To Present at Biotech Showcase Conference

 

Laval, Québec, CANADA – January 2, 2018 – Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D’Alvise, the company’s president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.

 

A live audio webcast of the presentation will be available under the “News & Investors” section of Acasti's website at www.acastipharma.com. A replay of the presentation will be available for 60 days following the event.

 

About Acasti Pharma

 

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.

 

# # #

 

Acasti Contact:

Jan D’Alvise

Chief Executive Officer

450-686-4555

[email protected]

www.acastipharma.com

 

Media Contact:

Jessica Dyas

Canale Communications

619-849-5385

[email protected]

 

Investor Relations Contact:

Glen Akselrod

Bristol Capital Ltd.

(905) 326-1888 ext 10

[email protected]

 

 

Page 1 of 1

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings